GlassScriptPhysician profile
Jonathan Lee Vellinga
NPI 1225291727
$1,248.76
in general payments reported to CMS, 2019-2025
22 companies · $392 in 2025
The $392 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2021: $11.58 · 2022: $117 · 2023: $116 · 2024: $473 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $980.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $165.33 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $128.97 | 2023-2024 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $127.70 | 2024-2025 | |
| Corcept Therapeutics | $107.68 | 2024-2025 | Korlym |
| Linvatec Corporation | $95.79 | 2019 | |
| Novo Nordisk INC | $90.69 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $81.03 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $78.72 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.95 | 2019-2025 | Xifaxan |
| Ibsa Pharma INC. | $42.80 | 2021-2022 | |
| Medtronic, INC. | $42.77 | 2025 | Symplicity G3 |
| Acella Pharmaceuticals, LLC | $29.96 | 2023-2025 | NP Thyroid 60 |
| Genzyme Corporation | $29.94 | 2024 | |
| Axsome Therapeutics, INC. | $22.42 | 2025 | Symbravo |
| Dexcom, INC. | $20.60 | 2024 | Dexcom G6 Transmitter |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $19.92 | 2022 | |
| Recordati_rare_diseases_inc. | $19.92 | 2025 | Isturisa |
| Edwards Lifesciences Corporation | $17.96 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Sanofi-Aventis U.S. LLC | $15.52 | 2019 | |
| Vyera Pharmaceuticals, LLC | $15.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.59 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.48 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Vellinga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.